Radioprotection of craniofacial bone growth

Journal of Craniofacial Surgery

Volumn 18, Issue 5, 2007, Pages 995-1000

  Gevorgyan, Artur ^a   La Scala, Giorgio C ^b   Neligan, Peter C ^c   Pang, Cho Y ^d   Forrest, Christopher R ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Amifostine; Bone development; Osteoblasts; Radiation; Radiation protective agents

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; CISPLATIN; FERRIC FERROCYANIDE; GRANISETRON; INTERLEUKIN 1ALPHA; METHYLXANTHINE; MISOPROSTOL; PENTETIC ACID; PENTOXIFYLLINE; POTASSIUM IODIDE; PROSTAGLANDIN E1 DERIVATIVE; SELENIUM; TEMPOL;

BONE DEVELOPMENT; CELL CULTURE; CRANIOFACIAL DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENDOTHELIUM CELL; FIBROBLAST; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NONHUMAN; OSTEOBLAST; OVARY CANCER; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; REVIEW;

AMIFOSTINE; ANIMALS; BONE AND BONES; CELL LINE; FACIAL BONES; GROWTH; MODELS, ANIMAL; RADIATION INJURIES, EXPERIMENTAL; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 34948815098     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/scs.0b013e31812f7596     Document Type: Review

References (52)

1. Bourhis J, Etessami A, Lusinchi A. New trends in radiotherapy for head and neck cancer. Ann Oncol 2005;16(Suppl 2):ii255-ii257
2. Poggi MM, Coleman CN, Mitchell JB. Sensitizers and protectors of radiation and chemotherapy. Curr Probl Cancer 2001;25:334-411
3. Seed TM. Radiation protectants: current status and future prospects. Health Phys 2005;89:531-545
4. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol 2000;72:425-435
5. MedImmune Oncology I. Ethyol® (Amifostine) for Injections. Gaithersburg, MD: MedImmune, 2005
6. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer 2001;92:914-923
7. Souid AK, Fahey RC, Dubowy RL, et al. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study. Cancer Chemother Pharmacol 1999;44:498-504
8. Bonner HS, Shaw LM. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 2002;42:166-174
9. Orditura M, De Vita F, Roscigno A, et al. Amifostine: a selective cytoprotective agent of normal tissues from chemoradiotherapy induced toxicity [Review]. Oncol Rep 1999;6:1357-1362
10. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer 1996;32A(Suppl 2):S5-S16
11. Murley JS, Constantinou A, Kamath NS, et al. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif 1997;30:283-294
12. Shen H, Chen ZJ, Zilfou JT, et al. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther 2001;297:1067-1073
13. North S, El-Ghissassi F, Pluquet O, et al. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 2000;19:1206-1214
14. Pluquet O, North S, Richard MJ, et al. Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem Pharmacol 2003;65:1129-1137
15. Pluquet O, North S, Bhoumik A, et al. The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem 2003;278:11879-11887
16. Mann K, Hainaut P. Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene 2005;24:3964-3975
17. Kataoka Y, Murley JS, Khodarev NN, et al. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine. Int J Radiat Oncol Biol Phys 2002;53:180-189
18. Constine LS, Rubin P, Gregory P. The differential protection by WR2721 of skin versus growing cartilage following irradiation in weanling rats. Radiat Res 1987;110:61-71
19. Tamurian RM, Damron TA, Spadaro JA. Sparing radiation-induced damage to the physis by radioprotectant drugs: laboratory analysis in a rat model. J Orthop Res 1999;17:286-292
20. Damron TA, Spadaro JA, Margulies B, et al. Dose response of amifostine in protection of growth plate function from irradiation effects. Int J Cancer 2000;90:73-79
21. Damron TA, Spadaro JA, Tamurian RM, et al. Sparing of radiation-induced damage to the physis: fractionation alone compared to amifostine pretreatment. Int J Radiat Oncol Biol Phys 2000;47:1067-1071
22. Damron TA, Margulies B, Biskup D, et al. Amifostine before fractionated irradiation protects bone growth in rats better than fractionation alone. Int J Radiat Oncol Biol Phys 2001;50:479-483
23. Spadaro JA, Baesl MT, Conta AC, et al. Effects of irradiation on the appositional and longitudinal growth of the tibia and fibula of the rat with and without radioprotectant. J Pediatr Orthop 2003;23:35-40
24. Damron TA, Margulies BS, Strauss JA, et al. Sequential histomorphometric analysis of the growth plate following irradiation with and without radioprotection. J Bone Joint Surg Am 2003;85-A:1302-1313
25. Margulies B, Morgan H, Allen M, et al. Transiently increased bone density after irradiation and the radioprotectant drug amifostine in a rat model. Am J Clin Oncol 2003;26:e106-e114
26. Damron TA, Mathur S, Horton JA, et al. Temporal changes in PTHrP, Bcl-2, Bax, caspase, TGF-beta, and FGF-2 expression following growth plate irradiation with or without radioprotectant. J Histochem Cytochem 2004;52:157-167
27. Damron TA, Spadaro JA, Horton JA, et al. Novel radioprotectant drugs for sparing radiation-induced damage to the physis. Int J Radiat Biol 2004;80:217-228
28. Damron TA, Spadaro JA, Horton JA, et al. Combinations of radioprotectants spare radiation-induced damage to the physis. Clin Orthop 2004:110-116
29. Spadaro JA, Horton JA, Margulies BS, et al. Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone. Int J Radiat Biol 2005;81:759-765
30. O'Donovan DA, Yeung I, Zeman V, et al. Radiation-induced craniofacial bone growth inhibition: development of an animal model. J Craniofac Surg 2001;12:533-543
31. Forrest CR, O'Donovan DA, Yeung I, et al. Efficacy of radioprotection in the prevention of radiation-induced craniofacial bone growth inhibition. Plast Reconstr Surg 2002;109:1311-1323. discussion 1324
32. La Scala GC, O'Donovan DA, Yeung I, et al. Radiation-induced craniofacial bone growth inhibition: efficacy of cytoprotection following a fractionated dose regimen. Plast Reconstr Surg 2005;115:1973-1985
33. La Scala GC, O'Donovan DA, Yeung I, et al. Radiation-induced craniofacial bone growth inhibition: hemodynamic effects with and without cytoprotection. Plast Reconstr Surg 2007: (In press)
34. O'Donovan DA, La Scala GC, Leong I, et al. Radiation-induced craniofacial bone growth inhibition: acute and long-term effects on bone histopathology with and without cytoprotection. Plast Reconstr Surg 2007: (In press)
35. Grdina DJ, Murley JS, Kataoka Y. Radioprotectants: current status and new directions. Oncology 2002;63(Suppl 2):2-10
36. Mori T, Watanabe M, Horikawa M, et al. WR-2721, its derivatives and their radioprotective effects on mammalian cells in culture. Int J Radiat Biol Relat Stud Phys Chem Med 1983;44:41-53
37. Hill RP, Rodemann HP, Hendry JH, et al. Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 2001;49:353-365
38. Mooteri SN, Podolski JL, Drab EA, et al. WR-1065 and radioprotection of vascular endothelial cells. Part II. Morphology. Radiat Res 1996;145:217-224
39. Rubin DB, Drab EA, Kang HJ, et al. WR-1065 and radioprotection of vascular endothelial cells. I. Cell proliferation, DNA synthesis and damage. Radiat Res 1996;145:210-216
40. Murley JS, Kataoka Y, Hallahan DE, et al. Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med 2001;30:1426-1439
41. Grdina DJ, Murley JS, Kataoka Y, et al. Differential activation of nuclear transcription factor kappaB, gene expression, and proteins by amifostine's free thiol in human microvascular endothelial and glioma cells. Semin Radiat Oncol 2002;12:103-111
42. Khodarev NN, Kataoka Y, Murley JS, et al. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int J Radiat Oncol Biol Phys 2004;60:553-563
43. Cohen SR, Bartlett SP, Whitaker LA. Reconstruction of late craniofacial deformities after irradiation of the head and face during childhood. Plast Reconstr Surg 1990;86:229-237
44. Jackson IT, Carls F, Bush K, et al. Assessment and treatment of facial deformity resulting from radiation to the orbital area in childhood. Plast Reconstr Surg 1996;98:1169-1180
45. Travis EL, Newman RA, Helbing SJ. WR 2721 modification of type II cell and endothelial cell function in mouse lung after single doses of radiation. Int J Radiat Oncol Biol Phys 1987;13:1355-1359
46. Travis EL, Parkins CS, Holmes SJ, et al. WR-2721 protection of pneumonitis and fibrosis in mouse lung after single doses of x rays. Int J Radiat Oncol Biol Phys 1984;10:243-251
47. Grdina DJ, Nagy B, Hill CK, et al. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthineguanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 1985;6:929-931
48. Grdina DJ, Sigdestad CP, Carnes BA. Protection by WR1065 and WR151326 against fission-neutron-induced mutations at the HGPRT locus in V79 cells. Radiat Res 1989;117:500-510
49. Zhang X, Lai PP, Taylor YC. Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR1065. Int J Radiat Oncol Biol Phys 1992;24:713-719
50. Gevorgyan AM, La Scala GC, Sukhu B, et al. An in vitro model of radiation-induced craniofacial bone growth inhibition. J Craniofac Surg 2007;18: (In press)
51. Gevorgyan AM, La Scala GC, Sukhu B, et al. Radiation-induced craniofacial bone growth inhibition: in vitro cytoprotection in the rabbit orbito-zygomatic complex periosteum-derived cell culture. Plast Reconstr Surg 2007; (In press)
52. Gevorgyan AM, Sukhu B, Neligan PC, et al. Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. Plast Reconstr Surg; (In press)